Quarterly sales of GSK's RSV vaccine dropped more than 70%, following narrower recommendations for who should get the shot.

Moderna’s (NASDAQ:MRNA) Q3 results confirmed on Thursday that the U.S. vaccine market for respiratory syncytial virus (RSV), ...

Moderna said on Friday Canada's health regulator has approved its vaccine for respiratory syncytial virus in adults 60 years ...

GSK has received Canadian approval for its respiratory syncytial virus vaccine in adults between 50 and 59, the company said ...

Moderna said on Friday Canada's health regulator has approved its vaccine for respiratory syncytial virus in adults 60 years ...

The British pharma’s experience during the third quarter mirrored that of rival Pfizer, which also reported lower sales of ...

To hear GSK CEO Emma Walmsley tell it, the third quarter presented “some challenges” for the drugmaker. | To hear GSK CEO ...

GSK has lowered its vaccine sales forecast for the year because of weak demand for its new respiratory syncytial virus jab Arexvy, sending the pharmaceutical group’s shares down more than 3 per cent ...

In the third quarter, GSK saw weaker-than-expected sales for its respiratory syncytial virus (RSV) and shingles vaccines.

GlaxoSmithKline (GSK) has received approval for its vaccine, AREXVY, in Canada to prevent lower respiratory tract disease ...